BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Stem Cells. Aug 26, 2026; 18(8): 120694
Published online Aug 26, 2026. doi: 10.4252/wjsc.120694
Table 2 Comparison of the complement alternative pathway, inflammatory markers, and stem cell indicators between end-stage renal disease patients and non-end-stage renal disease patients, mean ± SD/n (%)
Indicators
Non-ESRD (n = 224)
ESRD (n = 31)
t/χ2
P value
CFH (mg/L)612.75 ± 185.97547.72 ± 149.541.8640.063
CFB (mg/L)395.88 ± 85.99361.91 ± 77.084.112< 0.001a
CFI (mg/L)55.44 ± 8.9150.68 ± 6.959.452< 0.001a
SC5b-9 (mg/L)0.52 ± 0.060.54 ± 0.181.3300.185
C3a (mg/L)0.79 ± 0.110.65 ± 0.076.366< 0.001a
BAFF (ng/mL)4.34 ± 0.254.41 ± 0.311.4310.154
MCP-1 (pg/mL)227.98 ± 57.01289.56 ± 55.425.463< 0.001a
CXCL-10 (pg/mL)137.91 ± 25.94145.05 ± 34.181.3770.170
IL-6 (pg/mL)19.58 ± 3.5823.46 ± 5.665.211< 0.001a
TNF-α (pg/mL)21.65 ± 3.9526.95 ± 4.316.924< 0.001a
VSELs (events/600 μL whole blood)52.87 ± 6.4262.94 ± 12.936.986< 0.001a
HSCs (events/600 μL whole blood)81.47 ± 6.8883.32 ± 7.471.4190.157
EPCs (events/600 μL whole blood)40.25 ± 5.4238.57 ± 3.991.6730.096


Write to the Help Desk